SpringWorks Therapeutics Inc (NASDAQ:SWTX) has a beta value of 0.80 and has seen 1.41 million shares traded in the last trading session. The company, currently valued at $3.12B, closed the last trade at $39.02 per share which meant it gained $2.72 on the day or 7.49% during that session. The SWTX stock price is -38.19% off its 52-week high price of $53.92 and 48.26% above the 52-week low of $20.19. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.05 million shares traded. The 3-month trading volume is 1.07 million shares.
The consensus among analysts is that SpringWorks Therapeutics Inc (SWTX) is Buy stock at the moment, with a recommendation rating of 1.11. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.64.
SpringWorks Therapeutics Inc (NASDAQ:SWTX) trade information
Sporting 7.49% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the SWTX stock price touched $39.02 or saw a rise of 1.49%. Year-to-date, SpringWorks Therapeutics Inc shares have moved 6.90%, while the 5-day performance has seen it change 7.05%. Over the past 30 days, the shares of SpringWorks Therapeutics Inc (NASDAQ:SWTX) have changed 34.04%. Short interest in the company has seen 11.63 million shares shorted with days to cover at 13.14.
Wall Street analysts have a consensus price target for the stock at $76, which means that the shares’ value could jump 48.66% from current levels. The projected low price target is $50.0 while the price target rests at a high of $76.0. In that case, then, we find that the current price level is -94.77% off the targeted high while a plunge would see the stock gain -28.14% from current levels.
SpringWorks Therapeutics Inc (SWTX) estimates and forecasts
Figures show that SpringWorks Therapeutics Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -7.93% over the past 6 months, with this year growth rate of 39.42%, compared to 18.00% for the industry. Revenue growth from the last financial year stood is estimated to be 3,346.53%.
6 analysts offering their estimates for the company have set an average revenue estimate of 57.13M for the current quarter. 5 have an estimated revenue figure of 68.7M for the next ending quarter. Year-ago sales stood 5.45M and 21.01M respectively for this quarter and the next, and analysts expect sales will grow by 948.89% for the current quarter and 3,346.53% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -65.72% over the past 5 years.
SWTX Dividends
SpringWorks Therapeutics Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
SpringWorks Therapeutics Inc (NASDAQ:SWTX)’s Major holders
Insiders own 2.01% of the company shares, while shares held by institutions stand at 116.63% with a share float percentage of 119.02%. Investors are also buoyed by the number of investors in a company, with SpringWorks Therapeutics Inc having a total of 323.0 institutions that hold shares in the company. The top two institutional holders are FMR LLC with over 11.11 million shares worth more than $418.6 million. As of 2024-06-30, FMR LLC held 15.0638% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 6.54 million shares as of 2024-06-30. The firm’s total holdings are worth over $246.53 million and represent 8.8715% of shares outstanding.
